BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Company News  |  Deals

Philogen, Bayer deal

Philogen's most advanced compound, Darleukin ( L19-IL2), a fusion protein consisting of the human vascular targeting antibody L19 and IL-2, has completed Phase II testing to treat renal cell carcinoma....

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >